NEW YORK, Dec. 4, 2017 /PRNewswire/ -- Hoth Therapeutics
Inc. ("Hoth" or the "Company"), a development stage
biopharmaceutical company focused on unique targeted therapeutics
for patients suffering from indications such as atopic dermatitis,
also known as eczema, today announced the issuance of the first
U.S. patent relating to Hoth's BioLexa Platform. On
November 21, 2017, the United States
Patent and Trademark Office ("USPTO") issued U.S. Patent No.
9,821,063 entitled "Antimicrobial compositions of aminoglycosidic
antibiotics and zinc ion chelators specifically formulated for
enhanced inhibition of bacterial colonization and antibacterial
efficacy." The new patent is part of the technology portfolio
Hoth is developing under an exclusive license from the University of Cincinnati ("UC").
Hoth's BioLexa Platform is a proprietary, patented, drug
compound platform developed at UC. Dr. Andrew Herr, Ph.D, the developer of the
technology and a member of Hoth's Technology Advisory Board, is a
listed inventor on the new patent. The claims of the patent
encompass key pharmaceutical compositions for which Hoth intends to
pursue regulatory approval and commercialization.
Robb Knie, Hoth CEO stated, "We
are extremely pleased that the USPTO has issued this patent,
providing valuable intellectual property in our BioLexa Platform.
This patent is a key component to the growing value of the
Company."
Anthony Hayes, CEO of Spherix
Incorporated (NASDAQ: SPEX), which is a large shareholder of Hoth,
stated, "This new patent evidences the strength of our investment
in Hoth. We look forward to Hoth's pursuit of
commercialization of this valuable technology platform."
About Hoth Therapeutics Incorporated
Hoth Therapeutics Inc., a Nevada corporation, is a
development stage biopharmaceutical company focused on unique
targeted therapeutics for patients suffering from indications such
as atopic dermatitis, also known as eczema.
Forward Looking Statements
Certain statements in this
press release constitute "forward-looking statements" within the
meaning of the federal securities laws. Words such as "may,"
"might," "will," "should," "believe," "expect," "anticipate,"
"estimate," "continue," "predict," "forecast," "project," "plan,"
"intend" or similar expressions, or statements regarding intent,
belief, or current expectations, are forward-looking statements.
While the Company believes these forward-looking statements are
reasonable, undue reliance should not be placed on any such
forward-looking statements, which are based on information
available to us on the date of this release. These forward looking
statements are based upon current estimates and assumptions and are
subject to various risks and uncertainties, including without
limitation those set forth in the Company's filings with the
Securities and Exchange Commission (the "SEC"), not limited to Risk
Factors relating to its patent business contained therein. Thus,
actual results could be materially different. The Company expressly
disclaims any obligation to update or alter statements whether as a
result of new information, future events or otherwise, except as
required by law.
Contact:
Investor Relations Contact:
Phone: (646) 756-2997
Email: investorrelations@hoththerapeutics.com
www.hoththerapeutics.com
Spherix Contact:
Phone: (703) 992-9325
Email: info@spherix.com
www.spherix.com
View original
content:http://www.prnewswire.com/news-releases/hoth-therapeutics-inc-announces-issuance-of-first-us-patent-on-its-biolexa-platform-300565630.html
SOURCE Hoth Therapeutics Inc.